Core Viewpoint - The restructuring of Xinda Australia Fund's ownership and management has led to significant changes in its operational stability and performance, raising concerns about its future growth trajectory and investor confidence [1][6]. Management Changes - In December 2025, Xinda Australia Fund underwent multiple personnel changes, including the departure of Chairman Zhu Ruimin and the appointment of Tang Lunfei as the new chairman [2][3]. - Vice General Manager Lu Li also left the company, and the former General Manager Zhu Yongqiang retired after leading the fund to grow its management scale from 10 billion to 100 billion [2][3]. - The new chairman Tang Lunfei has extensive experience in risk management and compliance, which may influence the company's future direction [2]. Fund Manager Adjustments - Several fund managers were replaced in December, with notable attention on the departure of Yang Ke, the manager of the "Xinda Health China" fund, which has seen a significant decline in performance [3][4]. - Yang Ke's management saw a drastic reduction in assets from over 7 billion to 690 million, indicating a loss of investor confidence [5]. Performance and Financial Metrics - Xinda Australia Fund reported a significant decline in revenue and net profit, with 2024 figures showing revenue of 644 million and net profit of 101 million, both down sharply year-on-year [6]. - By mid-2025, the fund's management scale dropped from 1,374.51 billion to 1,030.06 billion, with a notable decrease in money market fund size [6]. - The fund faced regulatory issues, including a penalty for insider trading, which further impacted its reputation and operational stability [6][7]. Market Position and Future Outlook - The company is at a crossroads, needing to stabilize its core team, adjust investment strategies, and rebuild investor trust amidst a changing market environment [7]. - If the company can effectively integrate internal resources and refocus on research and investment capabilities, there remains potential for regaining investor confidence as market conditions improve [7].

Core Insights - The article provides an overview of the latest performance of various mutual funds, highlighting the top and bottom performers based on net asset value changes [1]. Fund Performance Summary Top Performing Funds - The top 10 funds with the highest net value growth include: 1. Guotou Ruijin Silver Futures (LOF) A: 2.3777, up 6.27% 2. Xinao Medical Health Mixed A: 1.3136, up 4.78% 3. Xinao Medical Health Mixed C: 1.3101, up 4.77% 4. GF Innovation Medical Two-Year Holding Mixed C: 0.9070, up 4.61% 5. GF Innovation Medical Two-Year Holding Mixed A: 0.9245, up 4.61% 6. Wanjia Global Growth One-Year Holding Mixed (QDII) C: 0.9410, up 4.34% 7. Wanjia Global Growth One-Year Holding Mixed (QDII) A: 0.9656, up 4.33% 8. Xinao Enjoy Life Mixed C: 1.2091, up 4.29% 9. Xinao Enjoy Life Mixed A: 1.2301, up 4.28% 10. GF Hong Kong-Shanghai Medical Mixed A: 1.1561, up 4.26% [2][3]. Bottom Performing Funds - The bottom 10 funds with the largest declines in net value include: 1. Dongfang Alpha Zhaoyang Mixed A: 0.5213, down 6.36% 2. Dongfang Alpha Zhaoyang Mixed E: 0.5144, down 6.35% 3. Great Wall Prosperity Growth Mixed C: 1.6053, down 6.22% 4. Great Wall Prosperity Growth Mixed A: 1.6280, down 6.22% 5. Xinyuan Industry Opportunity Mixed A: 1.1447, down 6.06% 6. Xinyuan Industry Opportunity Mixed C: 1.1432, down 6.06% 7. Huaan Big Security Theme Mixed C: 3.0600, down 5.99% 8. Huaan Big Security Theme Mixed A: 3.1370, down 5.97% 9. Zhongou High-end Equipment Stock Initiation C: 1.1549, down 5.79% 10. Zhongou High-end Equipment Stock Initiation A: 1.1731, down 5.79% [3]. Market Overview - The Shanghai Composite Index opened high but experienced wide fluctuations, closing with a small decline. The total trading volume reached 3.69 trillion, with a ratio of advancing to declining stocks at 1622:3729 [5]. - The leading sectors included insurance, which rose over 2%, while the lagging sectors were aviation, semiconductors, and telecommunications, which fell over 3% [5].

Core Insights - The A-share market has shown positive momentum at the beginning of 2026, prompting public funds to accelerate their investment strategies, with over ten public institutions resuming large-scale subscriptions for more than ten actively managed equity funds, many of which have seen net value growth exceeding 40% in the past year [1][2] Group 1: Fund Subscription Adjustments - Multiple high-performing equity funds have relaxed their subscription limits at the start of the year, with Penghua Fund announcing the resumption of large subscriptions for its Penghua Dynamic Growth Mixed Fund starting January 12, 2026, lifting the previous daily subscription cap of 1 million yuan [2] - Prior to this, Xinda Australia Fund had already adjusted its subscription rules on January 6, 2026, removing limits for institutional investors on its Xinao Medical Health Mixed A Fund, which previously had a daily subscription limit of 5 million yuan [2] - A total of over ten equity funds have resumed large subscriptions since the beginning of the year, with daily subscription limits ranging from 1 million to 50 million yuan, catering to various funding needs [2][3] Group 2: Performance and Market Outlook - The funds that have recently resumed large subscriptions generally exhibit strong performance, with several products reporting net value growth rates exceeding 40% over the past year, including the Xinao Medical Health Mixed A Fund, which achieved a remarkable 70.04% growth [3] - The chief economist of Qianhai Kaiyuan Fund indicated that the decision to relax subscription limits is based on confidence in performance and market opportunities, as A-share valuations are considered reasonable, supported by policy backing and economic recovery expectations [3] Group 3: Market Dynamics and Fund Strategy - The simultaneous relaxation of subscription limits is influenced by multiple factors, including the completion of year-end settlements by institutions like insurance companies, which opens a window for long-term capital allocation [4] - The expectation of a "spring rally" in the A-share market is increasing, enhancing the willingness of funds to attract new capital, while the relaxation of limits aligns with the marketing strategies of banks at the beginning of the year [4] - Industry experts suggest that the relaxation of subscription limits sends a positive signal to the market, with structural opportunities in sectors related to technology and high-end manufacturing expected to become core investment directions for funds [4]

Core Insights - The A-share market is experiencing a rebound, with the Shanghai Composite Index reaching historical highs, boosting investor confidence and leading to a resurgence in public funds [1] - Active equity funds, particularly those managed by Xinda Australia Fund, have shown remarkable performance, creating sustained value growth for investors [1][2] Fund Performance - Xinda Australia Fund's products, including Xinda Craftsmanship Return Mixed A, Xinda Preferred Life Mixed A, Xinda Medical Health Mixed A, and Xinda Performance Driven Mixed A, have achieved net value growth rates of 70.82%, 57.40%, 57.46%, and 51.72% respectively in 2025 [1] - According to Haitong Securities, these funds ranked in the top 10% of their category as of June 30, 2025, with respective rankings of 138/3751, 214/3751, 338/3751, and 162/3751 [1] - Over the past five years, Xinda Australia's equity products have yielded a return of 17.86%, ranking 47 out of 137 in the market, while the seven-year return reached 149.24%, placing second out of 115 [2] Investment Strategy - Xinda Australia Fund emphasizes a dual-driven approach of "talent + technology," utilizing intelligent analysis tools and multi-factor quantitative models to enhance decision-making efficiency [2] - The firm has actively responded to industry fee reforms, prioritizing investor benefits and reinforcing market trust [2] - The fund's investment strategy focuses on long-term value creation aligned with national industrial upgrading directions, aiming to provide sustainable returns for investors [2] Fund Manager Profiles - Xinda Craftsmanship Return Mixed Fund is managed by Zhang Mingye, who has a background in industry analysis and has been with Xinda Australia since 2020 [3] - Xinda Preferred Life Mixed Fund is managed by Yang Ke, who has experience in consumer industry research and has been with Xinda Australia since 2015 [4] - Xinda Medical Health Mixed Fund is currently managed by Li Diandian, who has a background in biochemistry and has been with Xinda Australia since 2020 [6] - Xinda Performance Driven Mixed Fund is managed by Liu Xiaoming, who has extensive experience in equity investment and joined Xinda Australia in 2021 [6]

Core Insights - The latest fund rating report from Tianxiang Investment Advisory highlights that seven equity products from Xinda Australia Fund Management Co., Ltd. achieved the highest five-star rating due to their long-term stable performance and excellent risk control capabilities [1] - The competition for ratings was intense, with only less than 6% of the 723 actively managed equity funds receiving a five-year five-star rating, and less than 11% and 4% of the 2796 mixed equity funds receiving three-year and five-year five-star ratings, respectively [1] Performance Metrics - Xinda Australia's products, including Xinao Advanced Manufacturing Stock A, Xinao Star Yi Mixed A/C, Xinao New Energy Selected Mixed A, Xinao Medical Health Mixed A, and Xinao Prosperity Preferred Mixed A, all received three-year five-star ratings [1] - Xinao Core Technology Mixed A stood out by receiving both three-year and five-year five-star ratings, showcasing the company's strong performance across multiple products [1] - According to Guotai Junan Securities, as of June 30, 2025, Xinao Advanced Manufacturing Stock A ranked in the top 1/5 percentile of active stock open-end funds over the past five years, placing 66th out of 376 products [1] Investment Strategy - Xinda Australia has been enhancing its investment research system, aiming to establish a benchmark for all categories of equity investment and continuously optimizing its active management capabilities [1] - The company has gathered a team of experienced fund managers with over ten years of practical experience, who are adept at deep research to uncover valuable investment targets, thereby building a solid moat for long-term equity investments [1] Industry Context - The five-star rating has become the "gold standard" for measuring the comprehensive strength of products as the regulatory framework for fund rating systems continues to improve [1] - The collective achievement of seven products by Xinda Australia not only demonstrates the company's "group combat" advantage in equity investment but also sends a positive signal to the market that fundamental research and long-term value investing remain core paths to achieving excess returns in volatile markets [1]